Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Statistics

Total Valuation

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. has a market cap or net worth of CNY 17.88 billion. The enterprise value is 16.46 billion.

Market Cap	17.88B
Enterprise Value	16.46B

Important Dates

The next estimated earnings date is Friday, October 25, 2024.

Earnings Date	Oct 25, 2024
Ex-Dividend Date	n/a

Share Statistics

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. has 264.71 million shares outstanding. The number of shares has increased by 8.53% in one year.

Shares Outstanding	264.71M
Shares Change (YoY)	+8.53%
Shares Change (QoQ)	+2.14%
Owned by Insiders (%)	29.35%
Owned by Institutions (%)	28.77%
Float	148.08M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	43.88
PB Ratio	11.41
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-71.30
EV / Sales	40.43
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-239.80

Financial Position

The company has a current ratio of 2.31, with a Debt / Equity ratio of 0.61.

Current Ratio	2.31
Quick Ratio	2.15
Debt / Equity	0.61
Debt / EBITDA	n/a
Debt / FCF	-13.93
Interest Coverage	-13.83

Financial Efficiency

Return on equity (ROE) is -14.78% and return on invested capital (ROIC) is -9.09%.

Return on Equity (ROE)	-14.78%
Return on Assets (ROA)	-7.80%
Return on Capital (ROIC)	-9.09%
Revenue Per Employee	474,601
Profits Per Employee	-269,103
Employee Count	867
Asset Turnover	0.14
Inventory Turnover	0.25

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +55.74% in the last 52 weeks. The beta is 0.62, so Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s price volatility has been lower than the market average.

Beta (5Y)	0.62
52-Week Price Change	+55.74%
50-Day Moving Average	57.14
200-Day Moving Average	52.49
Relative Strength Index (RSI)	61.93
Average Volume (20 Days)	3,360,472

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Suzhou Zelgen Biopharmaceuticals Co.,Ltd. had revenue of CNY 407.21 million and -230.89 million in losses. Loss per share was -0.87.

Revenue	407.21M
Gross Profit	375.52M
Operating Income	-372.37M
Pretax Income	-255.84M
Net Income	-230.89M
EBITDA	-334.59M
EBIT	-372.37M
Loss Per Share	-0.87

Full Income Statement

Balance Sheet

The company has 2.38 billion in cash and 956.56 million in debt, giving a net cash position of 1.42 billion or 5.36 per share.

Cash & Cash Equivalents	2.38B
Total Debt	956.56M
Net Cash	1.42B
Net Cash Per Share	5.36
Equity (Book Value)	1.57B
Book Value Per Share	5.92
Working Capital	1.54B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 13.52 million and capital expenditures -82.17 million, giving a free cash flow of -68.65 million.

Operating Cash Flow	13.52M
Capital Expenditures	-82.17M
Free Cash Flow	-68.65M
FCF Per Share	-0.26

Full Cash Flow Statement

Margins

Gross margin is 92.22%, with operating and profit margins of -91.44% and -56.70%.

Gross Margin	92.22%
Operating Margin	-91.44%
Pretax Margin	-62.83%
Profit Margin	-56.70%
EBITDA Margin	-82.17%
EBIT Margin	-91.44%
FCF Margin	-16.86%

Dividends & Yields

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.53%
Shareholder Yield	-8.53%
Earnings Yield	-1.29%
FCF Yield	-0.38%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. has an Altman Z-Score of 4.42.

Altman Z-Score	4.42
Piotroski F-Score	n/a